NOACs in AF: Consequences of Underdosing and NonAdherence

Slides:

Advertisements

Similar presentations

Improving Stroke Prevention in Patients With Atrial Fibrillation.

Advertisements

Introduction. Adult ADHD in the Real World: From Clinical Trials to Clinical Practice.

Addressing the Challenges in Primary and Secondary Stroke Prevention

Covering the Bases in Cardioversion

Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.

Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.

Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.

RESISTANT HYPERTENSION OR POOR PATIENT ADHERENCE? TIPS TO GAIN CONTROL

US Guidelines US Guidelines Low-risk Patients.

NOACs, AF, and PCI: What Do the Latest Data Suggest?

When Is Adding Aspirin to NOACs Worth the Risk?

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

Thrombosis, Cancer, and NOACs

The ABCs of AF.

Access to NOAC Therapy:

NOACs in Clinical Practice: Are They All the Same?

Appropriate Stroke Prevention Strategies in Atrial Fibrillation

Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.

A New Era for NOACs:.

Anticoagulation Highlights From the American Heart Association Meeting 2017.

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

Extended Half-life Factor Products in the Management of Hemophilia

Individualizing Prophylaxis in Hemophilia

Optimizing Outcomes in the Management of GIST

Resistant Hypertension

Oral Anticoagulants in AFa,b A Brief History.

Global Burden of VTE. Preventing Thrombosis During and Post-Hospitalization: New Paradigms in Clinical Care.

Surveying the Safety of NOACs in the Real World

Selecting NOACs for High-Risk Patients

NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS

How to Adjust Anticoagulant Dosing

Revealing Characteristics of Patients at High Risk for Developing Atrial Fibrillation.

The Essentials for Secondary Stroke Prevention

Assessing the Risk for Stroke in Patients With Atrial Fibrillation

Talking to Patients About Diabetes Management

Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:

Efficacy and Safety of Edoxaban in Patients With AF and HF

Access to NOAC Therapy:

TAVR and the Risk of Thrombosis

Adherence in SPAF: Measures to Improve Care

What Anticoagulant Registries Are Revealing

Learning Objectives Classification of VTE Goals of VTE Treatment.

Oral Anticoagulation in AF

Evaluating New Therapies in HF

Dos and Don’ts for High-Risk Elderly Patients With AF

Practical Considerations to Extend Treatment for VTE

Atrial Fibrillation.

Extraordinary Cases of VTE Prevention in Patients With Cancer

Taking the "Cryptogenic" Out of Cryptogenic Stroke

Anticoagulation and Thrombosis Management

Assessing Atrial Fibrillation: Real-World Data vs Clinical Trials

Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?

What You Didn't Know About AF and Renal Dysfunction

Cancer-Associated Thrombosis

Extended Half-life Factor Products in the Management of Hemophilia

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Managing Pulmonary Embolism Posthospital Discharge

NOACs in AF: Consequences of Underdosing and NonAdherence

The ABCs of AF.

Taking the "Cryptogenic" Out of Cryptogenic Stroke

5 Good Minutes on Atrial Fibrillation-related Stroke

At the Crossroads of Coagulation

How to Adjust Anticoagulant Dosing

Antiarrhythmic Drugs in AF

Uptitration of Medications in HF: Start Low but Aim High and Stay High

Real-World Data in Cardiology: Focus on Atrial Fibrillation

Extraordinary Cases in Stroke Prevention

What's New in NOACs in AF?.

Presentation transcript:

NOACs in AF: Consequences of Underdosing and NonAdherence

NOACs Have Revolutionized Stroke Prevention in AF

Translating NOAC Trial Results Into Benefits for Patients

NOACs for AF: Trial Design

Experience With Low-Dose NOACs From the Phase 3 AF Studies

Approved NOAC Dosing Regimens

How Are NOACs Prescribed in the Real World?

Why Do Physicians Underdose?

What Are the Consequences of Underdosing?

Underdosing: Who Is at Increased Risk?

ORBIT-II AF: Outcomes After Adjustment For Inappropriate Dosing

Do Current Prescribing Patterns Reflect RCT Dosing?

How Do We Address Underdosing?

How Do We Address Underdosing? (cont)

Medication Adherence: ABC Taxonomy

Gold Standard Measurement of Medication Nonadherence

Extent of Medication Nonadherence in NVAF

Consequences of Medication Nonadherence

Pharmacokinetic Considerations Suggest That Twice-Daily Regimen Increases Forgiveness for Similar Deviations in Adherence

Ways to Increase Adherence

Summary

Abbreviations